EVE Health Group Starts Stability Testing for Erectile Dysfunction, Dysmenorrhea Candidates

MT Newswires Live

Jun 02, 2025

EVE Health Group (ASX:EVE) said it started stability testing for its treatment candidates for erectile dysfunction and dysmenorrhea, according to a Monday Australian bourse filing.

The treatment candidates are in oral formulations, developed by Nextract.

Results from the testing will form a component of the technical dossier submitted to the Therapeutic Goods Administration, the filing said.

The company plans to submit both products for review in the coming months, and it expects to receive approvals before the end of the current year, per the filing. It completed registration with the Therapeutic Goods Administration as both a registered sponsor and a registered manufacturer.

EVE Health Group's acquisition of Nextract is expected to be completed on or around June 12, the filing said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2540750039"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540750039\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540750039?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-02 14:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540750039","market":"fut","top_or_hot":-1,"title":"EVE Health Group Starts Stability Testing for Erectile Dysfunction, Dysmenorrhea Candidates","media":"MT Newswires Live","content":"<html><body><p> EVE Health Group (ASX:EVE) said it started stability testing for its treatment candidates for erectile dysfunction and dysmenorrhea, according to a Monday Australian bourse filing.</p><p>The treatment candidates are in oral formulations, developed by Nextract.</p><p>Results from the testing will form a component of the technical dossier submitted to the Therapeutic Goods Administration, the filing said.</p><p>The company plans to submit both products for review in the coming months, and it expects to receive approvals before the end of the current year, per the filing. It completed registration with the Therapeutic Goods Administration as both a registered sponsor and a registered manufacturer.</p><p>EVE Health Group's acquisition of Nextract is expected to be completed on or around June 12, the filing said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EVE Health Group Starts Stability Testing for Erectile Dysfunction, Dysmenorrhea Candidates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEVE Health Group Starts Stability Testing for Erectile Dysfunction, Dysmenorrhea Candidates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-02 14:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> EVE Health Group (ASX:EVE) said it started stability testing for its treatment candidates for erectile dysfunction and dysmenorrhea, according to a Monday Australian bourse filing.</p><p>The treatment candidates are in oral formulations, developed by Nextract.</p><p>Results from the testing will form a component of the technical dossier submitted to the Therapeutic Goods Administration, the filing said.</p><p>The company plans to submit both products for review in the coming months, and it expects to receive approvals before the end of the current year, per the filing. It completed registration with the Therapeutic Goods Administration as both a registered sponsor and a registered manufacturer.</p><p>EVE Health Group's acquisition of Nextract is expected to be completed on or around June 12, the filing said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EVE","symbol_name":"EVe Mobility Acquisition Corp","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2540750039","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540750039","pubTimestamp":1748846483,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"EVE Health Group  said it started stability testing for its treatment candidates for erectile dysfunction and dysmenorrhea, according to a Monday Australian bourse filing.The treatment candidates are in oral formulations, developed by Nextract.Results from the testing will form a component of the technical dossier submitted to the Therapeutic Goods Administration, the filing said.The company plans to submit both products for review in the coming months, and it expects to receive approvals before the end of the current year, per the filing. It completed registration with the Therapeutic Goods Administration as both a registered sponsor and a registered manufacturer.EVE Health Group's acquisition of Nextract is expected to be completed on or around June 12, the filing said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EVE":"EVe Mobility Acquisition Corp","EVE.AU":"Eve Health Ltd","BK7141":"包装食品与肉类"},"translate_title":"EVE Health Group开始对勃起功能障碍、痛经候选人进行稳定性测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVE":1,"EVE.AU":0.9},"content_text":"EVE Health Group (ASX:EVE) said it started stability testing for its treatment candidates for erectile dysfunction and dysmenorrhea, according to a Monday Australian bourse filing.The treatment candidates are in oral formulations, developed by Nextract.Results from the testing will form a component of the technical dossier submitted to the Therapeutic Goods Administration, the filing said.The company plans to submit both products for review in the coming months, and it expects to receive approvals before the end of the current year, per the filing. It completed registration with the Therapeutic Goods Administration as both a registered sponsor and a registered manufacturer.EVE Health Group's acquisition of Nextract is expected to be completed on or around June 12, the filing said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}